Genomic DNA and associated cellular macromolecules (gDNA)

Genomic DNA and associated cellular macromolecules, collectively organized as chromatin, serve as the fundamental repository of genetic information and the primary template for all cellular processes, including replication and transcription (Alberts et al., Molecular Biology of the Cell). In pharmacology, this complex is a major therapeutic target for cytotoxic chemotherapy, particularly in the treatment of various cancers where the goal is to induce lethal damage in rapidly proliferating cells (Nature Reviews Cancer, 2005). Drugs such as alkylating agents form covalent bonds with DNA bases, while intercalators disrupt the helical structure, both of which stall replication forks and trigger apoptosis (StatPearls, 2023). Beyond oncology, genomic DNA is a target in gene therapy and certain antimicrobial strategies that aim to disrupt pathogen genetic material. However, because these agents often lack high specificity for malignant versus healthy cells, they are associated with significant side effects, including bone marrow suppression and the risk of secondary cancers due to their inherent mutagenic potential (IARC Monographs). Understanding the interaction between small molecules and the DNA-protein complex remains vital for developing more targeted therapies and managing the long-term safety profiles of traditional chemotherapeutics.

Other names

Deoxyribonucleic acidChromatinNuclear DNAGenomeDouble-stranded DNA

Drugs targeting genomic DNA typically act through covalent modification (alkylation), physical insertion between base pairs (intercalation), or the induction of single- and double-strand breaks, thereby inhibiting DNA replication and RNA transcription (StatPearls, 2023; NIH PubChem).